EVX-B4

EVX-B4 is a **novel vaccine candidate** in preclinical development, designed to prevent infections caused by **Group A Streptococcus (GAS)**, a pathogen responsible for conditions ranging from mild (e.g., strep throat, scarlet fever) to severe and life-threatening (e.g., rheumatic heart disease, necrotizing fasciitis, sepsis). The vaccine program is being developed by Evaxion using the company's proprietary **AI-Immunology™ platform**, which computationally identifies and validates new vaccine antigen targets, aiming to accelerate and improve vaccine design. There is currently no approved preventive vaccine for GAS. The addition of EVX-B4 to the pipeline was guided by global medical need and expert consultation, reflecting Evaxion’s strategic emphasis on infectious disease and vaccine innovation[1][2][4][5][8][14].